



PRIME

Prevention and Remediation of Insulin Multimorbidity in Europe H2020 – 847879

D1.6. – Report on incidence, risk, time trends and lifetime course of compulsive and (noncompulsive) brain disorders in Danish individuals with and without insulin-related morbidities

Dissemination level	Public
Contractual date of delivery	31.December.2022
Actual date of delivery	07.December 2022
Туре	Report
Version	1
Filename	PRIME_Deliverable Report_D1.6
Workpackage	1
Workpackage leader	Søren Dalsgaard(AU)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847879.

This report reflects only the author's views and the Commission is not responsible for any use that may be made of the information it contains.

Author list

Organisation	Name	Contact information
Aarhus University	Søren Dalsgaard	soeren.dalsgaard@regionh.dk
Aarhus University	Maria Theresa Wimberley Böttger	tw.ncrr@au.dk

Table of Contents

1.	Executive Summary	4
2.	Deliverable report	5
3.	Conclusion	5

1. Executive Summary

For the epidemiological investigations of bidirectional associations between diagnoses of somatic insulin-related diseases and of brain disorders (WP1, Objective 1), we used longitudinal data from Danish registers, including the Civil Registration System, Medical Birth Register, Psychiatric Central Research Register, National Patient Register, National Prescription Registry, and Statistics Denmark. The investigations resulted in the publication of a peer-reviewed scientific report (see the attached Wimberley et al. 2022).

We performed a comprehensive investigation of the associations between Type 2 diabetes (T2D) – one of the most prevalent insulin-related disorders worldwide – and a broad range of 16 different brain disorders, including compulsive disorders, such as OCD and anorexia, as well as many other non-compulsive psychiatric, and neurological disorders (Task 1). In a population-based cohort of 1.9 mill. individuals, we estimated the incidence of the different brain disorders in people with T2D, and compared it with the incidence in those without T2D. Linkage of Danish registers with up to five decades of continuously updated data enabled us to study the incidence across the lifespan in a large cohort, while taking into account the time trends in the incidence of the disorders as well as the influence of SES and parental factors by adjustment in the models. Moreover, we examined sex differences in the associations.

In pairwise analyses, we found T2D to be strongly associated with most mental disorders, though not with anorexia. We also found associations between T2D and inflammatory brain disorders, epilepsy, and migraine (but not amyotrophic lateral sclerosis and multiple sclerosis). In addition, we examined the influence of the temporal order of diagnoses on these associations, i.e., we estimated the risk of T2D in people with a prior diagnosis of the brain disorders, and vice-versa. Again, most mental disorders were associated with a subsequent risk of developing T2D (except for those with anorexia). Similarly, people with T2D were at increased risk of subsequently being diagnosed with a mental disorder, and here we also found an increased risk of anorexia in those with a prior diagnosis of T2D, compared to individuals without T2D. We also found associations between T2D and inflammatory brain disorders and epilepsy in both directions. Multiple sclerosis did not increase the risk of T2D. However, T2D was associated with an increased risk of developing multiple sclerosis.

For further details including background and aims, description of methods, and more results relevant for this deliverable, we refer to our paper, '*Temporally ordered associations between type 2 diabetes and brain disorders - a Danish register-based cohort study*', published in August 2022 in BMC Psychiatry. The supplement published next to the paper includes a table with the diagnostic classification of all the disorders studied along with four supplementary results tables.

2. Deliverable report

Results have been published open access by Wimberley et al., BMC Psychiatry (2022) 22-573.

https://doi.org/10.1186/s12888-022-04163-z (PDF of publication see Appendix 1)

3. Conclusion

Overall, we found that Type 2 diabetes was associated with an increased risk of most of the psychiatric and neurological disorders. These associations were consistently found in both directions, except for a few disorders, including anorexia and amyotrophic lateral sclerosis. Strongest associations were seen with psychiatric disorders, particularly other (i.e. non-anorectic) eating disorders and schizophrenia spectrum disorder.

Our findings emphasize the importance of monitoring people with type 2 diabetes as a high-risk group for mental health problems. Similarly, psychiatrists should be aware of the increased risk of developing type 2 diabetes when treating patients with a mental disorder. Both strategies could improve early identification and treatment of mental disorders and type 2 diabetes, respectively.

Supplement Material

Supplementary Table 1: Diagnostic classifications for definition of type 2 diabetes and selected brain disorders.

Disorder	ICD-10	ICD-8	Data source
Diabetes mellitus type 2	E11, 024.1	250	DNPR
Diabetic complications			
Diabetic cataract	H28.0	250.01	DNPR
Diabetic retinopathy	Н36.0	250.01	DNPR
Diabetic traction detachment of retina	H33.4B		DNPR
Diabetic peripheral angiopathy	179.2	250.04, 250.05	DNPR
Diabetic mononeuropathy	G59.0		DNPR
Diabetic polyneuropathy	G63.2	250.03	DNPR
Autonomic neuropathy in endocrine and metabolic diseases	G99.0		DNPR
Diabetic arthropathy	M14.2		DNPR
Neuropathic arthropathy	M14.6		DNPR
Glomerular disorders in diabetes mellitus	N08.3	250.02	DNPR
Any psychiatric disorders (used for parental history)	F00-F99	295-315	DPCRR
Psychiatric disorders			
OCD	F42	300.39	DPCRR, DNPR ^a

Disorder	ICD-10	ICD-8	Data source
ASD	F84 (excl. F84.2-4)	299.00-299.03	DPCRR, DNPR ^a
Anorexia nervosa	F50.0, F50.1	306.50	DPCRR, DNPR
Other eating disorder	F50.2, F50.3, F50.8, F50.9	306.58, 306.59	DPCRR, DNPR
Substance use disorder	F10-F19, F10 (alcohol), F12 (cannabis), F11,F13- 16,F18-19 (other illicit drugs)	291.x9, 294.39, 303.x9, 303.20, 303.28, 303.90, 304.x9	DPCRR, DNPR
Schizophrenia spectrum disorder	F20-F29	295.x9, 296.89, 297.x9, 298.29-298.99, 299.04, 299.05, 299.09, 301.83	DPCRR
Major depressive disorder	F32-F33	296.09, 296.29, 298.09, 300.49	DPCRR, DNPR
Bipolar disorder	F30-F31	296.19, 296.39, 298.19	DPCRR
Anxiety disorder	F40.00-F41.19, F4200-F43.10, F93	300.09, 300.29, 300.39	DPCRR
Personality disorder	F60	301.09, 301.29-301.99, 301.80, 301.81, 301.82, 301.84	DPCRR
ADHD	F90, F98.8	308.1	DPCRR, DNPR ^a
Neurological disorders			
Inflammatory brain diseases	G00-G09	320-324	DPCRR, DNPR
Amyotrophic lateral sclerosis	G12.2	348.09	DPCRR, DNPR
Epilepsy	G40-41	345, 309.49, 331.29	DPCRR, DNPR
Multiple sclerosis	G35	340	DPCRR, DNPR
Migraine	G43	346	DPCRR, DNPR

Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, DNPR: The Danish National Patient Register, DPCRR: The Danish Psychiatric Central Research Register, OCD: Obsessive-compulsive disorder.^a Diagnoses were obtained from DPCRR and from pediatric and neurology specialties in DNPR.

Supplementary table 2: Crude and adjusted estimates based on logistic regression analyses and temporally ordered Cox regression analyses.

	Disorder and type 2 diabetes			Disorder and subsequent type 2 diabetes			Type 2 diabetes and subsequent disorder		
Total N included = 1,883,198 ^a	Cases	Crude OR ^b (95% Cl)	Adjusted OR ^c (95% Cl)	Cases	Crude HR ^b (95% Cl)	Adjusted HR ^c (95% Cl)	Cases	Crude HR ^b (95% Cl)	Adjusted HR ^c (95% Cl)
Psychiatric disorders									
OCD	327	2.02 (1.81,2.26)	1.98 (1.76,2.21)	233	2.05 (1.80,2.33)	2.00 (1.76,2.28)	94	1.83 (1.49,2.25)	1.79 (1.45,2.20)
ASD	184	2.20 (1.89,2.55)	2.17 (1.87,2.53)	113	1.99 (1.66,2.40)	1.97 (1.64,2.38)	72	2.33 (1.83,3.05)	2.38 (1.87,3.03)
Anorexia nervosa	95	0.94 (0.77,1.15)	0.94 (0.77,1.16)	78	0.89 (0.71,1.11)	0.89 (0.72,1.12)	17	1.97 (1.21,3.19)	1.97 (1.21,3.20)
Other eating disorder	354	2.68 (2.40,2.99)	2.64 (2.36,2.94)	260	2.56 (2.26,2.89)	2.50 (2.21,2.82)	94	4.06 (3.29,5.00)	3.92 (3.18,4.84)
Substance use disorder	9,456	2.11 (2.06,2.16)	2.05 (2.01,2.10)	6,933	2.09 (2.04,2.14)	2.03 (1.98,2.08)	2,543	2.08 (1.99,2.16)	2.02 (1.94,2.10)
Schizophrenia spectrum disorder	3,082	2.82 (2.72,2.94)	2.73 (2.63,2.84)	2,740	2.91 (2.80,3.02)	2.81 (2.70,2.92)	351	2.02 (1.81,2.25)	1.94 (1.74,2.16)
Major depressive disorder	5,048	2.30 (2.23,2.37)	2.25 (2.18,2.32)	3,521	2.30 (2.23,2.38)	2.25 (2.17,2.32)	1,537	2.04 (1.94,2.15)	1.99 (1.89,2.09)
Bipolar disorder	936	2.20 (2.06,2.36)	2.17 (2.02,2.32)	658	2.30 (2.13,2.48)	2.25 (2.08,2.43)	284	1.85 (1.64,2.09)	1.82 (1.61,2.06)
Anxiety disorder	2,906	2.11 (2.03,2.19)	2.04 (1.97,2.13)	2,048	2.17 (2.07,2.26)	2.10 (2.01,2.20)	869	1.85 (1.72,1.98)	1.79 (1.67,1.92)
Personality disorder	4,075	2.51 (2.43,2.60)	2.43 (2.35,2.52)	3,597	2.51 (2.43,2.60)	2.44 (2.36,2.52)	482	2.08 (1.90,2.28)	2.03 (1.85,2.22)
ADHD	443	1.98 (1.80,2.19)	1.88 (1.70,2.07)	267	2.20 (1.95,2.47)	2.07 (1.84,2.32)	163	1.63 (1.39,1.91)	1.55 (1.32,1.81)
Neurological disorders									
Inflammatory brain diseases	424	1.75 (1.58,1.93)	1.73 (1.57,1.91)	267	1.49 (1.32,1.68)	1.48 (1.31,1.67)	157	2.53 (2.15,2.98)	2.51 (2.13,2.96)
Amyotrophic lateral sclerosis	28	1.07 (0.73,1.57)	1.07 (0.73,1.58)	12	1.27 (0.72,2.23)	1.25 (0.71,2.20)	16	1.09 (0.66,1.81)	1.09 (0.66,1.80)

	Disorder and type 2 diabetes			Disorder and subsequent type 2 diabetes			Type 2 diabetes and subsequent disorder		
Epilepsy	2,238	1.71 (1.64,1.79)	1.67 (1.60,1.75)	1,653	1.60 (1.52,1.68)	1.56 (1.49,1.64)	589	2.30 (2.11,2.50)	2.25 (2.06,2.44)
Multiple sclerosis	375	1.02 (0.92,1.13)	1.01 (0.91,1.12)	236	0.90 (0.79,1.03)	0.90 (0.79,1.02)	139	1.36 (1.15,1.61)	1.35 (1.14,1.60)
Migraine	1,540	1.30 (1.23,1.37)	1.29 (1.23,1.36)	1,166	1.37 (1.29,1.45)	1.37 (1.29,1.45)	377	1.090.98,1.21)	1.09 (0.98,1.20)

^a The two first analytic approaches includes the entire study population of 1,883,198 individuals. For the last approach (type 2 diabetes and subsequent brain disorder), only incident cases are included and hence the total number included in each analysis varies for each outcome, e.g. for OCD as the outcome (n = 1,880,480) and for ASD as the outcome (n=1,881,576).

^b Adjusted for sex and birth year.

^c Adjusted for sex, birth year, parental history of psychiatric disorders and type 2 diabetes. Estimates correspond to those reported and illustrated in Figures 1 and 2. Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, OCD: Obsessive-compulsive disorder.

	Di	sorder and subseq	uent type 2 diabet	es	Type 2 diabetes and subsequent disorder			
	Females (N=909,341)		Males (N=973,857)		Females (N=907,756 ^b)		Males (N=973,138 ^b)	
	Cases	Adjusted HR ^a (95% Cl)	Cases	Adjusted HR ^a (95% Cl)	Cases	Adjusted HR ^a (95% Cl)	Cases	Adjusted HR ^a (95% Cl)
Psychiatric disorders								
OCD	136	2.14 (1.81,2.54)	97	1.78 (1.46,2.17)	51	1.78 (1.34,2.35)	43	1.77 (1.30,2.41)
ASD	32	2.05 (1.45,2.90)	81	1.99 (1.60,2.47)	21	2.29 (1.48,3.56)	50	2.40 (1.80,3.21)
Anorexia nervosa ^c	NA	NA	NA	NA	NA	NA	NA	NA
Other eating disorder	238	2.26 (1.99,2.57)	22	3.49 (2.30,5.30)	79	3.66 (2.91,4.60)	15	6.06 (3.48,10.55)
Substance use disorder	2,079	2.18 (2.08,2.28)	3,893	1.97 (1.91,2.03)	917	2.14 (2.00,2.28)	1,606	1.97 (1.87,2.07)
Schizophrenia spectrum disorder	1,205	3.42 (3.22,3.62)	1,535	2.48 (2.36,2.61)	153	2.28 (1.94,2.68)	189	1.77 (1.53,2.05)
Major depressive disorder	2,014	2.45 (2.34,2.57)	1,504	2.01 (1.91,2.12)	734	1.94 (1.80,2.09)	793	2.00 (1.86,2.15)
Bipolar disorder	365	2.55 (2.30,2.83)	291	1.97 (1.75,2.21)	132	1.75 (1.47,2.09)	146	1.87 (1.58,2.21)
Anxiety disorder	1,140	2.17 (2.04,2.30)	906	2.01 (1.88,2.15)	440	1.86 (1.69,2.04)	418	1.71 (1.55,1.89)
Personality disorder	2,056	2.83 (2.70,2.96)	1,535	2.05 (1.95,2.16)	258	2.07 (1.83,2.34)	220	1.98 (1.73,2.27)
ADHD	105	2.39 (1.98,2.90)	177	1.95 (1.68,2.26)	72	1.76 (1.39,2.23)	89	1.40 (1.14,1.74)

Supplementary table 3: Temporally ordered analyses of sex-specific associations between diagnoses of brain disorders and type 2 diabetes

	Di	sorder and subseq	uent type 2 diabet	es	Type 2 diabetes and subsequent disorder			
Neurological disorder								
Inflammatory brain diseases	115	1.68 (1.40,2.01)	152	1.36 (1.16,1.60)	50	2.09 (1.57,2.78)	107	2.79 (2.28,3.41)
Amyotrophic lateral sclerosis ^c	NA	NA	NA	NA	NA	NA	NA	NA
Epilepsy	711	1.68 (1.56,1.81)	938	1.48 (1.39,1.58)	227	2.57 (2.24,2.94)	358	2.05 (1.84,2.29)
Multiple sclerosis	148	0.94 (0.80,1.11)	88	0.84 (0.68,1.03)	75	1.21 (0.97,1.53)	64	1.54 (1.20,1.98)
Migraine	784	1.42 (1.32,1.52)	382	1.28 (1.16,1.41)	281	1.18 (1.05,1.33)	93	0.87 (0.71,1.07)

^a Adjusted for birth year, parental history of type 2 diabetes and psychiatric disorders.

^b As only incident cases are included in this analysis, the study population varies for each outcome.

c Cases in males or females were too few to be reported, according to regulations at Statistics Denmark and CIRRAU.

Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, CIRRAU: Centre for Integrated Register-based Research at Aarhus University, OCD: Obsessive-compulsive disorder.

Supplementary Table 4: Adjusted estimates based on logistic regression analyses and temporally ordered Cox regression analyses without and with adjustment for highest attained level of education.

	Disorder and type 2 diabetes			Disorde	r and subsequent t	ype 2 diabetes	Type 2 diabetes and subsequent disorder		
Total N included = 1,883,198 ^a	Cases	Adjusted OR ^b (95% Cl)	Adjusted OR ^c (95% Cl)	Cases	Adjusted HR ^b (95% Cl)	Adjusted HR ^c (95% Cl)	Cases	Adjusted HR ^b (95% Cl)	Adjusted HR ^c (95% Cl)
Psychiatric disorders									
OCD	327	1.98 (1.76,2.21)	1.74 (1.55,1.95)	233	2.00 (1.76,2.28)	1.81 (1.59,2.06)	94	1.79 (1.45,2.20)	1.57 (1.27,1.93)
ASD	184	2.17 (1.87,2.53)	1.54 (1.32,1.79)	113	1.97 (1.64,2.38)	1.39 (1.15,1.67)	72	2.38 (1.87,3.03)	1.80 (1.42,2.30)
Anorexia nervosa	95	0.94 (0.77,1.16)	0.87 (0.71,1.07)	78	0.89 (0.72,1.12)	0.87 (0.69,1.08)	17	1.97 (1.21,3.20)	1.79 (1.10,2.90)
Other eating disorder	354	2.64 (2.36,2.94)	2.44 (2.19,2.73)	260	2.50 (2.21,2.82)	2.38 (2.11,2.69)	94	3.92 (3.18,4.84)	3.54 (2.86,4.37)
Substance use disorder	9,456	2.05 (2.01,2.10)	1.70 (1.66,1.74)	6,933	2.03 (1.98,2.08)	1.68 (1.64,1.72)	2,543	2.02 (1.94,2.10)	1.69 (1.62,1.76)
Schizophrenia spectrum disorder	3,082	2.73 (2.63,2.84)	2.21 (2.13,2.30)	2,740	2.81 (2.70,2.92)	2.34 (2.25,2.43)	351	1.94 (1.74,2.16)	1.61 (1.44,1.80)
Major depressive disorder	5,048	2.25 (2.18,2.32)	1.98 (1.92,2.04)	3,521	2.25 (2.17,2.32)	2.02 (1.95,2.09)	1,537	1.99 (1.89,2.09)	1.77 (1.68,1.86)
Bipolar disorder	936	2.17 (2.02,2.32)	1.95 (1.82,2.09)	658	2.25 (2.08,2.43)	2.08 (1.92,2.24)	284	1.82 (1.61,2.06)	1.66 (1.47,1.87)
Anxiety disorder	2,906	2.04 (1.97,2.13)	1.74 (1.68,1.81)	2,048	2.10 (2.01,2.20)	1.83 (1.75,1.92)	869	1.79 (1.67,1.92)	1.54 (1.44,1.65)
Personality disorder	4,075	2.43 (2.35,2.52)	1.98 (1.91,2.04)	3,597	2.44 (2.36,2.52)	2.03 (1.96,2.10)	482	2.03 (1.85,2.22)	1.69 (1.55,1.86)
ADHD	443	1.88 (1.70,2.07)	1.37 (1.24,1.51)	267	2.07 (1.84,2.32)	1.52 (1.35,1.71)	163	1.55 (1.32,1.81)	1.17 (1.00,1.37)

	ſ	Disorder and type 2	diabetes	Disorder and subsequent type 2 diabetes			Type 2 diabetes and subsequent disorder		
Neurological disorder									
Inflammatory brain diseases	424	1.73 (1.57,1.91)	1.62 (1.46,1.79)	267	1.48 (1.31,1.67)	1.41 (1.25,1.59)	157	2.51 (2.13,2.96)	2.39 (2.03,2.82)
Amyotrophic lateral sclerosis	28	1.07 (0.73,1.58)	1.06 (0.72,1.56)	12	1.25 (0.71,2.20)	1.26 (0.71,2.22)	16	1.09 (0.66,1.80)	1.09 (0.66,1.80)
Epilepsy	2,238	1.67 (1.60,1.75)	1.41 (1.35,1.48)	1,653	1.56 (1.49,1.64)	1.33 (1.26,1.39)	589	2.25 (2.06,2.44)	1.97 (1.81,2.14)
Multiple sclerosis	375	1.01 (0.91,1.12)	0.99 (0.89,1.10)	236	0.90 (0.79,1.02)	0.88 (0.77,1.00)	139	1.35 (1.14,1.60)	1.33 (1.12,1.58)
Migraine	1,540	1.29 (1.23,1.36)	1.24 (1.18,1.31)	1,166	1.37 (1.29,1.45)	1.32 (1.24,1.40)	377	1.09 (0.98,1.20)	1.06 (0.95,1.17)

^a The two first analytic approaches includes the entire study population of 1,883,198 individuals. For the last approach (type 2 diabetes and subsequent brain disorder), only incident cases are included and hence the total number included in each analysis varies for each outcome, e.g. for OCD as the outcome (n = 1,880,480) and for ASD as the outcome (n=1,881,576).

^b Adjusted for sex, birth year, parental history of type 2 diabetes and psychiatric disorders.

^c Additionally adjusted for highest obtained education level by age 30 years (not completed, low, intermediate, high).

Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, OCD: Obsessive-compulsive disorder.

		Main and alternative register-based T2DM definitions									
	Main (at least one OAD prescription or diagnosis) (n = 67,660)			o OAD prescriptions 1,701)	Clinical diagnosis ^c only (n = 41,498)						
Total N included = 1,883,198	Cases	Adjusted OR ^a (95% CI)	Cases	Adjusted OR ^a (95% Cl)	Cases	Adjusted OR ^a (95% CI)					
Psychiatric disorders											
OCD	327	1.98 (1.76,2.21)	314	2.00 (1.78,2.24)	219	2.12 (1.85,2.43)					
ASD	184	2.17 (1.87,2.53)	176	2.18 (1.87,2.55)	120	2.26 (1.88,2.72)					
Anorexia nervosa	95	0.94 (0.77,1.16)	NA ^b	NA ^b	77	1.23 (0.98,1.55)					
Other eating disorder	354	2.64 (2.36,2.94)	334	2.64 (2.36,2.95)	237	2.73 (2.39,3.12)					
Substance use disorder	9,456	2.05 (2.01,2.10)	9,107	2.06 (2.01,2.11)	6,820	2.44 (2.38,2.51)					
Schizophrenia spectrum disorder	3,082	2.73 (2.63,2.84)	2,950	2.72 (2.62,2.83)	1,951	2.70 (2.57,2.83)					
Major depressive disorder	5,048	2.25 (2.18,2.32)	4,828	2.25 (2.18,2.32)	3,377	2.43 (2.34,2.52)					
Bipolar disorder	936	2.17 (2.02,2.32)	897	2.17 (2.02,2.33)	598	2.21 (2.03,2.40)					
Anxiety disorder	2,906	2.04 (1.97,2.13)	2,773	2.04 (1.96,2.13)	1,903	2.15 (2.05,2.26)					
Personality disorder	4,075	2.43 (2.35,2.52)	3,907	2.44 (2.36,2.53)	2,735	2.60 (2.50,2.71)					
ADHD	443	1.88 (1.70,2.07)	411	1.83 (1.65,2.02)	275	1.85 (1.64,2.09)					

Supplementary table 5: Adjusted estimates based on logistic regression analysis applying the main and two alternative register-based T2DM definitions

Page **14** of **16**

	Main and alternative register-based T2DM definitions					
	Main (at least one OAD prescription or diagnosis) (n = 67,660)		Requiring at least two OAD prescriptions (n = 64,701)		Clinical diagnosis ^c only (n = 41,498)	
Neurological disorders						
Inflammatory brain diseases	424	1.73 (1.57,1.91)	408	1.74 (1.57,1.93)	334	2.22 (1.98,2.48)
Amyothrophic lateral sclerosis	28	1.07 (0.73,1.58)	NA ^b	NA ^b	20	1.25 (0.80,1.96)
Epilepsy	2,238	1.67 (1.60,1.75)	2,151	1.68 (1.60,1.75)	1,609	1.94 (1.85,2.05)
Multiple Sclerosis	375	1.01 (0.91,1.12)	361	1.02 (0.92,1.13)	254	1.13 (0.99,1.28)
Migraine	1,540	1.29 (1.23,1.36)	1,450	1.28 (1.21,1.35)	1,007	1.39 (1.30,1.48)

^a Adjusted for sex, birth year, parental history of type 2 diabetes and psychiatric disorders.

^b Differences in number of exposed cases between our main and second definition were too few for results to be reported, according to regulations at Statistics Denmark and CIRRAU.

^c Includes hospital diagnoses of T2DM (approximately 90% of cases) and diabetes-related complications as listed in supplementary table 1.

Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, CIRRAU: Centre for Integrated Register-based Research at Aarhus University, OAD: Oral anti-diabetics, OCD: Obsessive-compulsive disorder.

Appendix 1 – Publication Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study by Wimberley et al., BMC Psychiatry (2022) 22-573

RESEARCH

Open Access

Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study

Theresa Wimberley^{1,2*}, Henriette T. Horsdal^{1,2}, Isabell Brikell^{1,3}, Thomas M. Laursen^{1,2}, Aske Astrup^{1,2}, Giuseppe Fanelli^{4,5}, Janita Bralten⁴, Geert Poelmans⁴, Veerle Van Gils⁶, Willemijn J. Jansen⁶, Stephanie J. B. Vos⁶, Valérie Bertaina-Anglade⁷, Lucia Camacho-Barcia^{8,9,10}, Bernat Mora-Maltas^{8,9,10}, Fernando Fernandez-Aranda^{8,9,10,11}, Mònica B. Bonet^{10,12,13}, Jordi Salas-Salvadó^{10,13,14}, Barbara Franke^{4,15} and Søren Dalsgaard^{1,16,17,18}

Abstract

Background: Type 2 diabetes mellitus (T2DM) is linked with several neurodegenerative and psychiatric disorders, either as a comorbid condition or as a risk factor. We aimed to expand the evidence by examining associations with a broad range of brain disorders (psychiatric and neurological disorders, excluding late-onset neurodegenerative disorders), while also accounting for the temporal order of T2DM and these brain disorders.

Methods: In a population-based cohort-study of 1,883,198 Danish citizens, born 1955–1984 and followed until end of 2016, we estimated associations between T2DM and 16 brain disorders first diagnosed between childhood and mid-adulthood. We calculated odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) in temporally ordered analyses (brain disorder diagnosis after T2DM and vice versa), adjusted for sex, age, follow-up, birth year, and parental factors.

Results: A total of 67,660 (3.6%) of the study population were identified as T2DM cases after age 30 and by a mean age of 45 years (SD of 8 years). T2DM was associated with most psychiatric disorders. Strongest associations were seen with other (i.e. non-anorectic) eating disorders (OR [95% CI]: 2.64 [2.36–2.94]) and schizophrenia spectrum disorder (2.73 [2.63–2.84]). Among neurological disorders especially inflammatory brain diseases (1.73 [1.57–1.91]) and epilepsy (1.67 [1.60–1.75]) were associated with T2DM. Most associations remained in both directions in the temporally ordered analyses. For most psychiatric disorders, associations were strongest in females.

Conclusions: T2DM was associated with several psychiatric and neurological disorders, and most associations were consistently found for both temporal order of disorders. This suggests a shared etiology of T2DM and those brain disorders. This study can form the starting point for studies directed at further elucidating potential causal links between disorders and shared biological mechanisms.

Keywords: Epidemiology, Insulin signaling, Neurological disorders, Psychiatric disorders, Temporally ordered analysis, Type 2 diabetes mellitus

*Correspondence: tw.ncrr@au.dk

¹ NCRR - National Centre for Register-based Research, Aarhus BSS, Aarhus University, Fuglesangs Allé 26, DK-8210 Aarhus V, Denmark Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with a rising burden worldwide, particularly in Western Europe. In Denmark, the prevalence has increased from 1.2% in 1996 to 4.5% in 2016 [1], with a decrease in the incidence rate during the period 2011–2014, a trend also found in other studies [2-4]. T2DM typically onsets during late adulthood, but over the past decades the prevalence and incidence have particularly increased among adults aged 40-50 years compared with older age groups [1]. The etiology of T2DM includes lifestyle risk factors, such as obesity and low physical activity, but also an increased genetic liability to T2DM and psychiatric disorders [5, 6]. Across the lifespan, T2DM is associated with increased risks for adverse health outcomes, such as cardiovascular diseases, and premature death [7-9]. Studies have also found associations between T2DM and disorders of the brain, including vascular dementia and Alzheimer's disease [10], substance use disorder, schizophrenia, bipolar disorder, depression, personality disorder, and attention-deficit/ hyperactivity disorder (ADHD) [11-17], obsessive-compulsive disorder (OCD) [18], cognitive impairment [19], and also of filling a prescription for psychotropic drugs, including antidepressants, antipsychotics, and anxiolytics [20]. Recently, the term "insulinopathies of the brain" has been suggested to characterize these associations between T2DM and brain disorders [21, 22]. It should be noted that from here and onwards we use the term brain disorder when referring to a broad range of specific psychiatric and neurological disorders, although late-onset neurodegenerative disorders were not assessed in the present study.

To better understand the mechanisms underlying the co-occurrence of T2DM and brain disorders, the temporal order of disorder occurrence within an individual is important. Most of the previous studies, however, were cross-sectional or did not examine the temporal order of T2DM and the brain disorder bi-directionally. Estimating associations in both directions could provide additional clues about underlying mechanisms [23]. If an association is bi-directional, with comparable incidence rates of the brain disorder before and after T2DM, this may suggest that both disorders serve as independent risk factors for the onset of each other, or that the association is mainly driven by shared risk factors [24], such as unhealthy lifestyles [25] and common genetic risks [26, 27]. Previous studies have also suggested sex differences in the association between T2DM and brain disorders, though findings have been mixed [14, 28, 29], and more data on this is needed. In this study, we will add new knowledge on the sex-specific temporally ordered associations between T2DM and brain disorders.

Methods

Aims

To 1) estimate associations with T2DM for a broad range of both psychiatric and neurological disorders, 2) perform temporally ordered analyses to explore whether timing of the disorders influences the strength of the associations, and 3) estimate sex differences in these associations.

Design

Cohort study based on governmental data collected prospectively for administrative purposes and stored in nationwide Danish registers, accessible to researchers through Statistics Denmark.

Setting

Data sources

The Danish registers contain individual-level information on all Danish citizens, with each register capturing a different set of medical or socio-demographic information. The Danish Civil Registration System established in 1968 holds information on sex, date of birth and death, continuously updated information on place of living, and enables linkage with parental information [30]. Information on hospital contacts and diagnoses (main and supplementary) was available in the Danish National Patient Register and the Danish Psychiatric Central Research Register, which include inpatient contacts since 1977 and 1969, respectively, as well as outpatient and emergency room contacts since 1995 [31]. Diagnoses were classified according to the International Classification of Disease version 8 (ICD-8 [32]) until 1993, and version 10 (ICD-10 [33]) from 1994 onwards. Medication information was retrieved from the Danish National Prescription Registry, which includes information on all prescriptions redeemed at a Danish pharmacy since 1995 [34]. Information on education was available in the Education Registers at Statistics Denmark [35]. All the registers include an anonymized version of the unique personal identification number assigned to everyone at birth or immigration, which enables linkage across the registers on the individual level.

Study population

We included all individuals born in Denmark between 1955 and 1984, who were alive and residing in Denmark at age 30 years and could be linked to both parents. This cohort was chosen to enable identification of registered diagnoses of disorders occurring both early (childhood/ adolescence) and later in life (adulthood) in the same individuals.

Definition of T2DM

Date of first T2DM status was defined either with a clinical diagnosis of T2DM or the prescription of an oral antidiabetic drug (OAD, ATC codes A10B), whichever appeared first in the register after the age of 30 years. Additionally, some cases were identified based on having a hospital diagnosis of a T2DM-related complication as previously suggested [36]. For ICD-8 and ICD-10 codes, see Supplementary Table 1. To minimize misclassification of type 1 diabetes mellitus as T2DM cases, individuals only diagnosed or treated with OADs before age 30 years (but not later) were not included in our definition, inspired by previous register-based research [36]. In line with previous research [1], we ignored metformin prescriptions in females under age 40 years, as these could likely have been prescribed for polycystic ovarian syndrome. Women were thus defined as T2DM at first appearance of the other above-mentioned criteria after age 30 or at first redeemed metformin prescription after age 40.

Definitions of brain disorders

Brain disorders were defined based on ICD disease categories with a sufficient number of cases both before and after T2DM in the same study cohort reaching a maximum age of 62 years, and hence did not include late-onset neurodegenerative disorders. Thus, we included the following psychiatric and neurological disorders: 1) psychiatric disorders: Obsessive-compulsive disorder (OCD), autism spectrum disorder (ASD), anorexia nervosa, other eating disorders, substance use disorder, schizophrenia spectrum disorders, major depressive disorder, bipolar disorder, anxiety disorders, personality disorders, and ADHD; 2) neurological disorders: Inflammatory brain diseases (including infections), amyotrophic lateral sclerosis (ALS), epilepsy, multiple sclerosis, and migraine. Information on ICD-8 and ICD-10 codes and data source for the diagnostic categories can be found in Supplementary Table 1.

Covariates

The incidence of T2DM and the brain disorders we study differs between females and males, and hence analyses were adjusted for sex. To account for changes in the incidence of the disorders over time, analyses were adjusted for birth year. Psychiatric disorders and T2DM in parents were included as potential confounders, and measured at the time the individual reached age 30 years (baseline), in line with a previous study [16]. Parental psychiatric disorder were identified if at least one parent had a registered diagnosis in the Danish Psychiatric Central Research Register. Parental T2DM was based on diagnoses only (Supplementary Table 1), due to low coverage of prescription data in the parental generation.

Statistical analysis

We used different approaches to study the association between T2DM and the brain disorders of interest. First, we estimated the overall association between the brain disorder of interest and T2DM by the odds ratio (OR) from logistic regression (i.e., the temporal order of the two was not considered in this analysis). We adjusted for the variation in length of follow-up between individuals by including the age at end of follow-up as a continuous covariate in the model.

Second, in temporally ordered analyses, we estimated hazard ratios (HRs) from Cox regression analyses for the association between the brain disorder and subsequent diagnosis of T2DM and vice versa, using age as the underlying time scale. Individuals were followed from age 30 years and until either the date of outcome, or censored at date of emigration from Denmark, death, or end of the study period (December 31, 2016). The exposure of interest (i.e., the brain disorder or T2DM) was included time-dependently after age 30 years. When we considered T2DM as the exposure and a brain disorder as the subsequent outcome, the study cohort excluded individuals with a previous diagnosis of the brain disorder of interest before age 30 years.

Third, due to sex differences in the incidence of brain disorders and T2DM, we performed analyses for males and females separately. All analyses were adjusted for the following confounders: Sex (except those stratified by sex), birth year, and parental diagnoses of T2DM and any psychiatric disorder, prior to the date the individual reached age 30 years.

In supplementary analyses, we included education as an additional covariate in the models, to examine the influence of (a proxy of) socio-economic status on the association. This was defined as the highest attained level of education of the individual by age 30 years, categorized as: Not completed primary school, low (primary school), intermediate (high school/vocational training), and high level (higher education). Moreover, we repeated the logistic regression analyses with two alternative register-based T2DM definitions: 1) Restricting to at least two OAD prescriptions as have been used in previous research [1], and 2) restricting to hospital diagnoses to evaluate the robustness of results across severity level of T2DM.

Proportional hazards were checked by log-minus-log survival plots. All estimates are accompanied by 95% confidence intervals (CIs). All analyses were conducted in Stata version 16 (StataCorp, College Station, Tex.).

Results

Descriptive statistics

The study cohort included a total of 1,883,198 individuals, of whom 48.3% were females and the mean age at the end of follow-up was 46.6 years (standard deviation (SD) 8.4). During follow-up 5.4% of the study population emigrated from Denmark and 2.8% died. We identified 67,660 (3.6%) individuals as T2DM cases with a mean age of 45.1 years (SD=7.7) at first presentation according to our registerbased definition. Number of cases for the different brain disorders and distributions of these by sex, age at diagnosis and end of follow-up, and parental history of T2DM and psychiatric disorders can be found in Table 1.

Associations between brain disorders and T2DM

Associations with T2DM were found for most of the brain disorders studied when not considering the temporal order of diagnoses. The associated brain disorders were OCD, ASD, eating disorders (except anorexia nervosa), substance use disorder, schizophrenia spectrum disorder, major depressive episode, bipolar disorder, anxiety, personality disorder, ADHD, inflammatory brain disease, and epilepsy. No clear evidence of an association was found for anorexia nervosa, ALS, or multiple sclerosis as reflected by adjusted ORs close to the null (0.94, 1.07, and 1.01, respectively) and the width of the accompanying 95% confidence intervals. Adjusted ORs

 Table 1
 Characteristics of the full cohort and of individuals with specific psychiatric and neurological disorders

	Brain disorder cases ^a n (%)	Type 2 diabetes cases ^b n (%)	Female sex n (%)	Age (years) at first diagnosis Mean (SD)	Age (years) at end of follow- up ^c Mean (SD)	Parental history of psychiatric disorder n (%)	Parental history of type 2 diabetes n (%)
Total study popula- tion ($n = 1,883,198$)	-	67,660 (3.6)	909,341 (48.3)	-	46.6 (8.4)	260,463 (13.8)	102,382 (5.4)
Psychiatric disorde	rs						
OCD	6856 (0.4)	327 (4.8)	4209 (61.4)	45.1 (7.7)	42.7 (7.8)	1621 (23.6)	504 (7.4)
ASD	3594 (0.2)	184 (5.1)	1145 (31.9)	32.9 (9.4)	42.0 (7.8)	834 (23.2)	244 (6.8)
Anorexia nervosa	4846 (0.3)	95 (2.0)	4592 (94.8)	30.5 (12.4)	41.8 (7.6)	1023 (21.1)	275 (5.7)
Other eating disorder	7646 (0.4)	354 (4.6)	7286 (95.3)	23.8 (8.6)	40.6 (6.6)	1694 (22.2)	579 (7.6)
Substance use disorder	138,410 (7.3)	9456 (6.8)	49,432 (35.7)	27.8 (8.6)	46.4 (8.5)	33,167 (24.0)	9564 (6.9)
Schizophrenia spectrum disorder	33,603 (1.8)	3082 (9.2)	14,037 (41.8)	33.0 (11.5)	46.4 (8.5)	9704 (28.9)	2389 (7.1)
Major depressive disorder	73,497 (3.9)	5048 (6.9)	44,532 (60.6)	30.5 (9.4)	46.1 (8.3)	17,849 (24.3)	4997 (6.8)
Bipolar disorder	12,397 (0.7)	936 (7.6)	7056 (56.9)	36.2 (9.5)	47.2 (8.4)	3535 (28.5)	691 (5.6)
Anxiety	47,922 (2.5)	2906 (6.1)	28,556 (59.6)	37.1 (9.8)	45.2 (8.2)	12,291 (25.6)	3497 (7.3)
Personality disorder	55,572 (3.0)	4075 (7.3)	32,715 (58.9)	35.2 (9.7)	45.6 (8.5)	15,798 (28.4)	3969 (7.1)
ADHD	10,523 (0.6)	443 (4.2)	4178 (39.7)	30.0 (8.8)	41.2 (6.8)	3138 (29.8)	969 (9.2)
Neurological disor	ders						
Inflammatory brain diseases	7777 (0.4)	424 (5.5)	3516 (45.2)	27.1 (16.6)	45.2 (8.4)	1296 (16.7)	490 (6.3)
Amyotrophic lateral sclerosis	544 (0.0)	28 (5.1)	209 (38.4)	44.5 (9.7)	50.0 (7.7)	64 (11.8)	25 (4.6)
Epilepsy	39,634 (2.1)	2238 (5.6)	18,445 (46.5)	26.9 (14.4)	46.0 (8.3)	7405 (18.7)	2733 (6.9)
Multiple sclerosis	9860 (0.5)	375 (3.8)	6672 (67.7)	36.9 (8.7)	48.0 (7.8)	1322 (13.4)	575 (5.8)
Migraine	35,799 (1.9)	1540 (4.3)	26,018 (72.7)	34.5 (11.0)	46.9 (8.0)	6070 (17.0)	2006 (5.6)

^a Number of cases refer to those in the total study population during follow-up and not all cases are included in the separate analyses examining the temporal order of type 2 diabetes and brain disorder. Note that groups of brain disorders are not mutually exclusive, i.e. individuals may have several brain disorder diagnoses before end of follow-up

^b Type 2 diabetes are only considered after age 30, i.e. individuals that were only diagnosed or treated with oral antidiabetics before age 30 were not included as type 2 diabetes cases

^c Age at end of follow-up equals age at death. Emigration, or end of study, whichever comes first. Note that the varying age at end of follow-up is accounted for in the statistical analyses but not in the descriptive table

Abbreviations: ADHD: attention-deficit/hyperactivity disorder. ASD: Autism spectrum disorder. OCD: Obsessive-compulsive disorder

are presented in Fig. 1, and the number of cases as well as crude and adjusted ORs are shown in Supplementary Table 2. Almost all psychiatric disorders were associated with T2DM. Strongest associations were observed for eating disorders other than anorexia nervosa (adjusted OR [95% CI]: 2.64 [2.36–2.94]) and for schizophrenia spectrum disorder (2.73 [2.63–2.84]). Among the neurological disorders, associations were found for inflammatory brain diseases (1.73 [1.57–1.91]), epilepsy (1.67 [1.60–1.75]), and migraine (1.29 [1.23–1.36]). Virtually no differences were observed in crude and adjusted estimates.

Temporally ordered analyses

When examining the association between a brain disorder and subsequent T2DM, the estimates were very similar to those seen in the logistic regression, with increased rates of T2DM for all brain disorders, except for anorexia nervosa (adjusted HR [95% CI]: 0.89 [0.72– 1.12]), ALS (1.25 [0.71–2.20]), and multiple sclerosis (0.90 [0.79–1.02]) (Fig. 2a).

When examining the opposite temporal order of the disorders, i.e. T2DM first and brain disorder later, the pattern was overall similar, though with some noticeable differences. T2DM was associated with all the examined psychiatric disorders, now also anorexia nervosa (adjusted HR [95% CI]: 1.97 [1.21–3.20]). Furthermore, among the neurological disorders, an association with later multiple sclerosis was also observed (1.35 [1.14–1.60]), while an association with later migraine was less clear as observed by a smaller estimated effect size with a 95% confidence interval overlapping 1 (1.09 [0.98–1.20]) (Fig. 2b).

Overall, the proportionality assumptions were fulfilled in most analyses. However, in the second approach (T2DM after brain disorder), proportionality was not fulfilled for anorexia nervosa, with rates indicating a positive association with the incidence of T2DM at earlier ages and a negative association in later years of follow-up.

Sex differences in associations between T2DM and brain disorders

No significant sex differences were seen for OCD and ASD across the analytical approaches (Fig. 3 and Supplementary Table 3). For most other psychiatric disorders, associations were slightly stronger in females than in males. For anorexia nervosa, the adjusted OR was slightly below 1 in both females (0.95 [0.77–1.17]) and males (0.81 [0.36–1.84]) and with broad 95%



Association between type 2 diabetes and brain disorders



Temporally ordered associations between type 2 diabetes and brain disorders

Fig. 2 Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) based on temporally ordered analyses for the association between type 2 diabetes and included psychiatric and neurological disorders. Analyses were adjusted for sex, birth year, and parental history of psychiatric disorders and type 2 diabetes. **a** Individuals (n = 1,883,198) were followed for type 2 diabetes from age 30 until end of follow-up, and the brain disorder of interest were included as a time-dependent exposure variable after age 30, and time-fixed for disorders diagnosed before age 30. N = 1,883,198**b** Individuals were followed for the brain disorder of interest from age 30 until end of follow-up, and type 2 diabetes status was included as a time-dependent exposure. For the last approach (type 2 diabetes and subsequent brain disorder), only incident cases were included and hence the total number of individuals included in each analysis varied for each outcome, e.g. for OCD as the outcome (n = 1,880,480) and for ASD as the outcome (n = 1,881,576). Minimally adjusted estimates as well as number of exposed cases can be seen in Supplementary Table 2. Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism spectrum disorder, OCD: Obsessive-compulsive disorder

confidence intervals, particularly for males. Numbers were too low to conduct sex-specific temporally ordered analyses. In contrast to most psychiatric disorders, the association between other eating disorders and T2DM was stronger in males (adjusted OR [95% CI]: 4.18 [2.93–5.96]) than in females (2.52 [2.24–2.83]) in logistic regression analyses but also in the temporally ordered analyses (Supplementary Table 3). Among the neurological disorders, estimates of the associations with epilepsy, and migraine were highest in females and confidence intervals did not overlap the estimates for males (Fig. 3 and Supplementary Table 3); for migraine diagnosed after T2DM, the association was less clear in females (adjusted HR [95%

CI] = 1.18 [1.05,1.33]) and the adjusted HR was below 1 in males, but with 95% confidence limits overlapping 1 (0.87 [0.71-1.07]).

Influence of educational attainment and different definitions of T2DM

Associations estimated in the main models remained after further adjustment for highest attained level of education, though estimates were attenuated (Supplementary Table 4). Similarly, our estimates of the logistic regression analyses across different T2DM definitions were largely unchanged, though increased for several of the disorders when restricting to hospital diagnoses only (Supplementary Table 5).

	a) Fe	males	b) Mal	b) Males		
	OR (95% CI)		OR (95% CI)			
Psychiatric disorders						
OCD	2.09 (1.80-2.43)	F # -I	1.80 (1.52-2.15)	F#-1		
ASD	2.17 (1.64-2.87)	⊢ ₩1	2.20 (1.84-2.63)	⊦ ₩-1		
Anorexia nervosa	0.95 (0.77-1.17)	⊢ ₩-1	0.81 (0.36-1.84)			
Other eating disorder	2.52 (2.24-2.83)	HH	4.18 (2.93-5.96)	⊢ ×		
Substance use disorder	2.21 (2.12-2.30)	н	1.97 (1.92-2.03)	н		
chizophrenia spectrum disorder	3.34 (3.15-3.54)	н	2.41 (2.29-2.54)	н		
Major depressive disorder	2.38 (2.29-2.49)	н	2.06 (1.97-2.15)	н		
Bipolar disorder	2.35 (2.14-2.58)	Herei	1.97 (1.78-2.18)	H		
Anxiety disorder	2.13 (2.02-2.24)	н	1.94 (1.83-2.06)	ы		
Personality disorder	2.79 (2.67-2.92)	н	2.03 (1.93-2.14)	н		
ADHD	2.15 (1.85-2.51)	H++-I	1.74 (1.53-1.97)	⊢ ⊷ I		
Neurological disorders						
Inflammatory brain diseases	1.77 (1.51-2.07)	⊢• -i	1.70 (1.50-1.94)	H++-I		
Amyotrophic lateral sclerosis	1.59 (0.88-2.87)	H	0.85 (0.51-1.40) 🛛 🛏			
Epilepsy	1.83 (1.71-1.95)	н	1.56 (1.47-1.65)	н		
Multiple sclerosis	1.01 (0.88-1.16)	H=1	1.00 (0.85-1.18)	H-H		
Migraine	1.36 (1.28-1.45)	н	1.17 (1.06-1.28)	H		
-	0	.5 1 2 4	0.5	1 2 4		

for temporally ordered analyses can be seen in Supplementary Table 3. Abbreviations: ADHD: attention-deficit/hyperactivity disorder, ASD: Autism

Sex-specific associations between type 2 diabetes and brain disorders

Discussion

In this most comprehensive cohort study of nearly 1.9 million adults, we investigated associations between T2DM and psychiatric and neurological disorders using different analytic approaches. In both the logistic regression (where the temporal order of disease occurrence was ignored) and in Cox regression models (temporally ordered analysis), we consistently found that T2DM was associated with the majority of the examined brain disorders. Out of the 16 disorders investigated, 15 showed significant association with T2DM in at least one of the analyses. This included a wide range of psychiatric disorders, as well as some neurological disorders, including inflammatory brain diseases, epilepsy and migraine. While most brain disorders were associated with T2DM was

spectrum disorder, OCD: Obsessive-compulsive disorder

only associated unidirectionally with later diagnosed anorexia nervosa and multiple sclerosis, and the association with migraine was mainly evident, when considered prior to diabetes diagnosis, and we found no evidence of an association with ALS. For several of the psychiatric disorders (schizophrenia spectrum disorder, major depressive episode, bipolar disorder, anxiety, personality disorder, and ADHD), associations with subsequent T2DM were stronger than for incident diagnoses following T2DM.

The underlying mechanisms for associations between T2DM and brain disorders are largely unknown, though there is evidence for shared risk factors, both environmental and genetic [37]. Indeed, it has been hypothesized that the dysregulation of insulin signaling as observed in T2DM, metabolic syndrome, and obesity also extends to the brain in so-called "insulinopathies of the brain" [21].

Prior brain imaging studies offer some support for this concept, documenting gray matter changes in patients with T2DM, when compared with controls [38]. Also in recent genetic studies examining pathways contributing to compulsivity-related mental disorders and traits, insulin signaling has been identified as an important mechanism involved [39, 40].

Temporal order of T2DM and brain disorders

Few previous studies have investigated the development of psychiatric disorders both before and after T2DM diagnosis. Such temporally ordered analyses of the bidirectional associations provide new additional knowledge about mechanisms involved in the comorbidity, as compared to cross-sectional or uni-directional analyses.

For the association of psychiatric disorders and subsequent T2DM, our results replicate previous findings of increased risk of T2DM in individuals with psychiatric disorders, including substance use disorder, schizophrenia, depression, bipolar disorder, personality disorder, and ADHD, all with similar effect sizes as ours, despite a younger cohort in our study and differences in T2DM definitions [13, 14, 17, 41]. Our study also adds to the literature by demonstrating significant positive associations of other specific psychiatric disorders, namely OCD, ASD, other (non-anorectic) eating disorders, and anxiety, with subsequent diagnoses of T2DM.

For the opposite temporal order of occurrence of diagnoses, previous studies have found that patients with T2DM had increased risk of subsequent schizophrenia and bipolar disorder [41], and of filling a prescription for psychotropic medications [20]. The findings for schizophrenia and bipolar disorder are replicated and extended by our study, showing that these effects are bidirectional. Our finding of a bidirectioncal relation between T2DM and major depressive disorder also corroborates previous findings [13]. Furthermore, our study adds to the literature with novel findings of bidirectional associations for other eating disorder than anorexia, substance use disorder, anxiety disorder, personality disorder, and inflammatory brain disorders. This may suggest that shared risk factors are at play. Indeed, recent data-driven genome-wide approaches indicate that T2DM and most of the psychiatric disorders share genetic risk factors [42]. Still, for several of the disorders, estimated effects were of different size in the two temporally ordered analyses, which could be explained by specific disease-related risk factors influencing the association in the one direction. Additionally, we found associations in both directions for T2DM with ASD and ADHD. However, these results should be interpreted with caution due to less register coverage and potential diagnostic delay for these childhood disorders.

The increased risk of eating disorders observed after T2DM may to some extent be explained by recommended changes in dietary patterns following diagnosis of T2DM. For anorexia nervosa we found that individuals previously diagnosed with T2DM also had an increased risk for later-diagnosed anorexia nervosa, but we did not find evidence for an association in the opposite direction. This may also suggest that those diagnosed with anorexia nervosa late in adulthood may differ from cases diagnosed during adolescence. Little is known about phenomenological differences in the two age groups of anorexia cases; from the existing literature, it is unclear whether a first diagnosis of anorexia nervosa in later adulthood truly represents late-onset of the disorder or simply diagnostic delay of a pre-existing disorder [43]. For the associations between T2DM and eating disorders other than anorexia nervosa, results from the temporally ordered analyses showed higher effect sizes for developing the eating disorder after T2DM (with a 4-fold increased risk) than for the opposite direction (where it was a 2-fold increased risk). One possible explanation of this could be, that late onset-eating disorders (other than anorexia nervosa) are associated with higher rates of premorbid obesity, when compared to those with the typical onset eating disorder subtype [44]. In addition, the duration of the eating disorder, the trajectory of body mass index (BMI) over time, and the eating disorder subtype seem to be crucial to shed some light on the nature of this relationship [45].

Many of our findings related to neurological disorders are in line with previous research. Studies have found epilepsy to be associated with later T2DM [46] and also vice-versa [47], and associations between T2DM and subsequent risk of inflammatory brain disorders [48]. In contrast, our finding of inflammatory brain disorders being associated with increased risk of developing T2DM is novel, as far as we know, though this was previously hypothesized in a review [49]. A previous study suggested a protective effect of T2DM on ALS in European individuals [50], while we did not find much evidence of an inverse association in any of our analyses, but number of ALS cases with T2DM was small as reflected by the broad confidence intervals.

Findings on associations between migraine and T2DM have suggested another pattern. We found that migraine was associated with increased risk of T2DM, but found less clear evidence for an association between T2DM and subsequent migraine. In line with our findings, a prospective survey of more than 70,000 women in France, found that prior migraine was associated with increased incidence of T2DM (HR = 1.16; 1.06–1.27), while current

active migraine was associated with a lower risk of T2DM (HR = 0.80; 0.67 - 0.96) [51].

For multiple sclerosis, we also found an association only in one direction, i.e. that individuals with T2DM were at increased risk of later multiple sclerosis (but not vice-versa). One previous study also found increased risk of multiple sclerosis after T2DM, but did not examine the bi-directionality of the association [52]. Interestingly, there has been an increase in the incidence of especially late-onset multiple sclerosis over the past decades [53]. This trend coincides with increases in the incidence of T2DM [1]. Furthermore, previous research indicate a causal relationship between obesity and later multiple sclerosis [54]. Our finding that T2DM was only associated with later-onset multiple sclerosis may indicate a potentially causal link between T2DM or other insulinrelated disorders and later development of multiple sclerosis, but this finding needs replication in different cohorts.

Sex differences in associations between T2DM and brain disorders

Sex differences in the associations with T2DM were most pronounced for psychiatric disorders, with associations stronger in females than in males. These results are in line with previous research demonstrating stronger associations between OCD, anxiety, depression, bipolar disorder, and schizophrenia and T2DM in females, compared to males [18, 41, 55]. For migraine and epilepsy, we similarly observed stronger associations with T2DM in females, than in males. Interestingly, we did not find a statistically significant association between T2DM and subsequent risk of migraine in males, and the point estimate was even below 1 (HR=0.87; 0.71-1.07). In a large nationwide register-based study from Norway, T2DM was associated with a reduced risk of subsequent migraine with a tendency to be more pronounced in males (HR = 0.82), than in females (HR = 0.91) [56]. In contrast, associations between T2DM and other (nonanorectic) eating disorders were stronger in males, compared with females, actually bidirectionally. A previous study from Finland also found that males with other eating disorders had higher risks of developing T2DM, than females [57]. This may partly be explained by a higher BMI in males, compared with females with other eating disorders [58]. Sex differences were less clear in the associations with subsequent depression, bipolar, anxiety, or personality disorder.

Strengths and limitations

The major strength of the present study is the use of data from the nationwide registers, continuously updated for decades, and with virtually complete coverage. The Page 9 of 12

clinical diagnoses are in general of good validity [31], though some diagnoses, such as OCD, have only been validated in children [59].

Our study also has several limitations. First, we only include data from hospital contacts, not diagnoses made by psychiatrists, neurologists, or general physicians in private practices. Hence, we may mainly capture the more severe cases, and our results may not be generalizable to milder cases. For T2DM, we reduced this potential bias by also including prescriptions of OADs, thereby capturing a large part of T2DM cases treated solely by general physicians. Our sensitivity analyses restricting to hospital-diagnosed T2DM confirms such a selection bias and potential ascertainment bias as associations were generally stronger compared to our main definition including prescription data. Still, misclassification by not correctly identifying all T2DM cases or by including some with type 1 diabetes cannot be ruled out. Second, as in other studies, the date of first diagnosis may not represent the onset of the disorder, e.g. first diagnosis of ASD or ADHD may be in adolescence or adulthood, although a childhood-onset is a diagnostic prerequisite for these disorders [60, 61]. Similarly, T2DM has a gradual onset, often asymptomatic initially and may also remain undiagnosed for several years [62]. Thus, such diagnostic delays may reduce the validity of some of the temporally ordered analyses and complicate interpretation of results from an etiological perspective. Particularly among females under age 40, the onset of T2DM may be biased by some delay, and incidence may be slightly underestimated, as we ignore potential cases of polycystic ovarian syndrome (those only prescribed metformin before age 40), which may be misclassified.

Third, the inclusion of only incident brain disorder cases in the temporally ordered analyses of T2DM and subsequent brain disorders may have led to an underestimation of these associations, because younger age of onset of psychiatric or neurological disorders is typically associated with more severe pathology. For some of the brain disorders, we identified few incident cases after T2DM diagnosis, and estimates should be interpreted with caution. Fourth, to study associations with both early and late diagnosis of brain disorders we used the same study population for all analyses, and hence only cases with a T2DM diagnosis before age 62 years were included. While this enabled us to estimate associations with brain disorders occurring early in life, a major part of later-diagnosed cases with T2DM were not included. Consequently, we could not estimate associations with late-onset neurodegenerative disorders, such as dementia and Alzheimer's disease, associations which have been previously documented, also based on Danish registry data [10]. Similarly, information on

mental disorders was not available from early childhood for individuals born in earliest calendar years. However, the incidence of such diagnoses during the 1970's was extremely low, with an annual incidence of 17 per 100,000 children under age 15 years and 80% of those were readmitted after the age of 16 years [63]. For all study participants, we had complete coverage from age 14 years (or younger) and up to 32 years of coverage after age 30. Moreover, all analyses were adjusted for calendar year of birth and length of follow-up to minimize the potential influence of calendar time trends and differences in observation time between individuals. Finally, our observational data cannot inform about potential causality between T2DM and the development of brain disorders. Analyses were not adjusted for diverse variables such as BMI or other lifestyle factors including dietary intake or smoking, as such data was not available, and this may have influenced estimates towards a possible overestimation of the association. We did not develop unique adjustment models for each pairwise analysis, and we did not include information on the use of different types of medication (e.g. antipsychotics or antidiabetics). Rather, to keep analyses tractable and estimates comparable, we used the same adjustments across models and in both directions. Estimates were only slightly attenuated after adjustment for parental diagnoses and additional adjustment for level of education of the individual.

Our study adds to the body of existing knowledge by examining a broad spectrum of brain disorders and their associations with T2DM in a large populationbased cohort. We also report novel findings on temporal ordering of co-occurrence, showing e.g. increased risk for anorexia nervosa and multiple sclerosis after T2DM, but not in the other direction. Replication of these findings is needed before any firm conclusions can be drawn. Future research on associations between T2DM and brain disorders should examine confounding and/or mediating effects of lifestyle factors and psychotropic medications. To elucidate the potential causal mechanisms, future epidemiological, genetic, and bioinformatic studies could assess to what extent brain disorders and T2DM are linked through shared familial risk.

Abbreviations

ADHD: Attention-deficit/hyperactivity disorder; ASD: Autism spectrum disorder; ATC, OAD: Oral antidiabetic drug; OCD: Obsessive-compulsive disorder; T2DM: Type 2 diabetes mellitus; ALS: Amyothropic lateral sclerosis; ATC: Anatomical Therapeutic Chemical; CI: Confidence interval; HR: Hazard ratio; ICD: International Statistical Classification of Diseases; OAD: Oral antidiabetic drug; OR: Odds ratio.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12888-022-04163-z.

Additional file 1: Supplementary Table 1. Diagnostic classifications for definition of type 2 diabetes and selected brain disorders. Supplementary Table 2. Crude and adjusted estimates based on logistic regression analyses and temporally ordered Cox regression analyses. Supplementary Table 3. Temporally ordered analyses of sex-specific associations between diagnoses of brain disorders and type 2 diabetes. Supplementary Table 4. Adjusted estimates based on logistic regression analyses and temporally ordered Cox regression analyses without and with adjustment for highest attained level of education. Supplementary Table 5. Adjusted estimates based on logistic regression analysis applying the main and two alternative register-based T2DM definitions.

Acknowledgements

The author group thank the funding agencies for their support.

Authors' contributions

TW, HTH, and SD designed the study in collaboration, with scientific input also from IB, and TML, and design decisions were discussed with all co-authors. TW performed data-management and -analyses. TW and SD wrote the first draft of the manuscript. BF coordinated the collaboration within the PRIME consortium. All authors critically reviewed/edited the manuscript and approved the final version.

Funding

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847879 (PRIME). This study reflects only the authors' view, and the European Commission is not responsible for any use that may be made of the information it contains. Dr. Brikell is funded by a postdoctoral grant from Hjärnfonden. Dr. Salas-Salvadó is partially supported by ICREA under the ICREA Academia programme. CIBEROBN is an initiative of the Carlos III Health Institute, Spain. Dr. Dalsgaard's research is supported by grants from The Lundbeck Foundation (IPSYCH grant no R248–2017-2003), and the European Commission (Horizon 2020, grant no 667302).

The study funders was not involved in the design of the study; the collection, analysis, and interpretation of the data; writing the report; and did not impose any restrictions regarding the publication of the report.

Availability of data and materials

The data that support the findings of this study are available from Statistics Denmark. The data access required the completion of a detailed application form from the Danish Data Protection Agency, the Danish National Board of Health and Statistics Denmark. For more information on accessing the data, see http://www.dst.dk.

Declarations

Ethics approval and consent to participate

The study was approved by the Danish Data Protection Agency, and data access was agreed by Statistics Denmark and the Danish Health Data Authority. Approval by the Ethics Committee and written informed consent were not required for register-based projects, cf. LBK nr 1338 af 01/09/2020, \$10 Bekendtgørelse af lov om videnskabsetisk behandling af sundhedsvidenskabelige forskningsprojekter og sundhedsdatavidenskabelige forskningsprojekter [Act no. 1338 of 1 September 2020, section 10 on research ethics for administration of health scientific research projects and health data scientific research projects]. All data were de-identified and not recognizable at an individual level.

Consent for publication

Not applicable

Competing interests

WJJ received research support from Biogen. BF received educational speaking fees from Medice. No other potential conflicts of interest were reported.

Author details

¹NCRR - National Centre for Register-based Research, Aarhus BSS, Aarhus University, Fuglesangs Allé 26, DK-8210 Aarhus V, Denmark. ²CIRRAU - Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark. ³Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁴Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. ⁵Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ⁶Department of Psychiatry and Neuropsychology, School for Mental Health and NeuroScience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands. ⁷Biotrial Neuroscience, Rennes, France. ⁸Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain. ⁹Psychiatry and Mental Health Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, Barce-Iona, Spain.¹⁰Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. ¹¹Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.¹²Departament de Bioguímica i Biotecnologia, Universitat Rovira i Virgili, Reus, Spain.¹³Institut d'Investigació Sanitària Pere Virgili (IISPV). Hospital Universitari San Joan de Reus, Reus, Spain. ¹⁴Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Universitat Rovira i Virgili, Reus, Spain. ¹⁵Department of Psychiatry, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. ¹⁶iPSYCH - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen and Aarhus, Aarhus, Denmark.¹⁷Center for Child and Adolescent Psychiatry, Mental Health Services of the Capital Region, Copenhagen, Denmark.¹⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Received: 21 March 2022 Accepted: 7 July 2022 Published online: 26 August 2022

References

- Carstensen B, Rønn PF, Jørgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care. 2020;8:e001071. https://doi.org/10.1136/ bmjdrc-2019-001071.
- Ruiz PLD, Stene LC, Bakken IJ, Haberg SE, Birkeland KI, Gulseth HL. Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study. Diabetologia. 2018;61(11):2310–8.
- 3. Selvin E, Ali MK. Declines in the incidence of diabetes in the U.S.-Real Progress or artifact? Diabetes Care. 2017;40(9):1139–43.
- Knudsen JS, Knudsen SS, Hulman A, Witte DR, Gregg EW, Lauritzen T, et al. Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: a Danish 24-year populationbased study. Lancet Reg Health Eur. 2022;14:100291.
- Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat Commun. 2018;9(1):2941.
- Su MH, Shih YH, Lin YF, Chen PC, Chen CY, Hsiao PC, et al. Familial aggregation and shared genetic loading for major psychiatric disorders and type 2 diabetes. Diabetologia. 2022;65(5):800–10. https://doi.org/10. 1007/s00125-022-05665-x. Epub 2022 Feb 23. PMID: 35195735.
- Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59(8):1692–701.
- Davis WA, Zilkens RR, Starkstein SE, Davis TM, Bruce DG. Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle diabetes study phase I. Diabetologia. 2017;60(1):89–97.
- Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17(1):145.

- Katon W, Pedersen HS, Ribe AR, Fenger-Gron M, Davydow D, Waldorff FB, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. 2015;72(6):612–9.
- Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Borglum AD, Christensen MK, et al. Association between mental disorders and subsequent medical conditions. N Engl J Med. 2020;382(18):1721–31.
- Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174(7):686–94. https://doi.org/10. 1176/appi.ajp.2016.16040442. Epub 2017 Jan 20. PMID: 28103712.
- Renn BN, Feliciano L, Segal DL. The bidirectional relationship of depression and diabetes: a systematic review. Clin Psychol Rev. 2011;31(8):1239–46.
- Lindekilde N, Scheuer SH, Diaz LJ, Rubin KH, Plana-Ripoll O, Henriksen JE, et al. Risk of developing type 2 diabetes in individuals with a psychiatric disorder: a Nationwide register-based cohort study. Diabetes Care. 2022;45(3):724–33. https://doi.org/10.2337/dc21-1864.
- Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale metaanalysis. World Psychiatry. 2016;15(2):166–74.
- Takayanagi Y, Ishizuka K, Laursen TM, Yukitake H, Yang K, Cascella NG, et al. From population to neuron: exploring common mediators for metabolic problems and mental illnesses. Mol Psychiatry. 2021;26(8):3931–42.
- Chen Q, Hartman CA, Haavik J, Harro J, Klungsoyr K, Hegvik TA, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit/ hyperactivity disorder: a population-based cross-sectional study. Plos One. 2018;13(9):e0204516.
- Isomura K, Brander G, Chang Z, Kuja-Halkola R, Ruck C, Hellner C, et al. Fernandez de la Cruz L: metabolic and cardiovascular complications in obsessive-compulsive disorder: a Total population, sibling comparison study with long-term follow-up. Biol Psychiatry. 2018;84(5):324–31.
- Mallorqui-Bague N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvado J, Cuenca-Royo A, et al. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep. 2018;8(1):16128.
- Rohde C, Schmitz N, Thomsen RW, Østergaard SD. Incident psychopharmacological treatment and psychiatric hospital contact in individuals with newly developed type 2 diabetes - a register-based cohort study. Acta Neuropsychiatr. 2021;33(2):72–84. https://doi.org/10.1017/neu.2020. 39. Epub 2020 Oct 28. PMID: 33109286.
- Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME). https://cordis.europa.eu/project/id/847879.
- 22. Fanelli G, Franke B, De Witte W, Ruisch IH, Haavik J, van Gils V, et al. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. Transl Psychiatry. 2022;12(1):59.
- 23. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–7.
- Weissman MM, Brown AS, Talati A. Translational epidemiology in psychiatry: linking population to clinical and basic sciences. Arch Gen Psychiatry. 2011;68(6):600–8.
- Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19(3):360–80.
- Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179(7):1469–1482 e1411.
- Fanelli G, Franke B, De Witte W, Ruisch IH, Haavik J, van Gils V, Jansen WJ, Vos SJB, Lind L, Buitelaar JK et al: Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. Transl Psychiatry. 2022;12(1):59. https://doi.org/10.1038/s41398-022-01817-0. PMID: 35165256; PMCID: PMC8844407.
- Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and Meta-analysis. JAMA Psychiatry. 2016;73(3):247–59.
- Chireh B, D'Arcy C. Shared and unique risk factors for depression and diabetes mellitus in a longitudinal study, implications for prevention: an analysis of a longitudinal population sample aged 45 years. Ther Adv Endocrinol Metab. 2019;10:2042018819865828.

- Pedersen CB. The Danish civil registration system. ScandJPublic Health. 2011;39(7 Suppl):22–5.
- Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.
- 32. World Health Organization. International classification of diseases: manual of the international statistical classification of diseases, injuries and causes of death (ICD-8), vol. 8. rev. Geneva: WHO; 1967.
- World Health Organization. The ICD-10 classification of mental and Behavioural disorders. Diagnostic criteria for research. 1st ed. Geneva: WHO; 1993.
- Pottegård A, Schmidt SA, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798–798f. https://doi.org/10.1093/ije/ dyw213. PMID: 27789670; PMCID: PMC5837522.
- 35. Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7 Suppl):91–4.
- 36. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide casecontrol study. Pharmacoepidemiol Drug Saf. 2011;20(4):331–7.
- Hubel C, Gaspar HA, Coleman JRI, Hanscombe KB, Purves K, Prokopenko I, et al. Genetic correlations of psychiatric traits with body composition and glycemic traits are sex- and age-dependent. Nat Commun. 2019;10(1):5765.
- Roy B, Ehlert L, Mullur R, Freeby MJ, Woo MA, Kumar R, et al. Regional brain gray matter changes in patients with type 2 diabetes mellitus. Sci Rep. 2020;10(1):9925.
- Bralten J, Widomska J, Witte W, Yu D, Mathews CA, Scharf JM, et al. Shared genetic etiology between obsessive-compulsive disorder, obsessivecompulsive symptoms in the population, and insulin signaling. Transl Psychiatry. 2020;10(1):121.
- 40. van de Vondervoort I, Poelmans G, Aschrafi A, Pauls DL, Buitelaar JK, Glennon JC, et al. An integrated molecular landscape implicates the regulation of dendritic spine formation through insulin-related signalling in obsessive-compulsive disorder. J Psychiatry Neurosci. 2016;41(4):280–5.
- Takayanagi Y, Ishizuka K, Laursen TM, Yukitake H, Yang K, Cascella NG, et al. From population to neuron: exploring common mediators for metabolic problems and mental illnesses. Mol Psychiatry. 2021;26(8):3931–42. https://doi.org/10.1038/s41380-020-00939-5. Epub 2020 Nov 10. PMID: 33173197; PMCID: PMC8514126.
- Fanelli G, Franke B, Witte W, Ruisch I, Haavik J, Gils V. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. medRxiv. 2021. https://doi.org/10.1101/2021.05.28.21258000.
- Scholtz S, Hill LS, Lacey H. Eating disorders in older women: does late onset anorexia nervosa exist? Int J Eat Disord. 2010;43(5):393–7.
- Bueno B, Krug I, Bulik CM, Jimenez-Murcia S, Granero R, Thornton L, et al. Late onset eating disorders in Spain: clinical characteristics and therapeutic implications. J Clin Psychol. 2014;70(1):1–17.
- Agüera Z, Vintró-Alcaraz C, Baenas I, Granero R, Sánchez I, Sánchez-González J, et al. Lifetime weight course as a phenotypic marker of severity and therapeutic response in patients with eating disorders. Nutrients. 2021;13(6):2034. https://doi.org/10.3390/nu13062034. PMID: 34199265; PMCID: PMC8231878.
- Shlobin NA, Sander JW. Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: a scoping review. Epilepsy Behav. 2020;106:107043.
- Lu CL, Chang YH, Sun Y, Li CY. A population-based study of epilepsy incidence in association with type 2 diabetes and severe hypoglycaemia. Diabetes Res Clin Pract. 2018;140:97–106.
- 48. Kim EJ, Ha KH, Kim DJ, Choi YH. Diabetes and the risk of infection: a National Cohort Study. Diabetes Metab J. 2019;43(6):804–14.
- Han C, Rice MW, Cai D. Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am J Physiol Endocrinol Metab. 2016;311(1):E32–41.
- Zeng P, Wang T, Zheng J, Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17(1):225.
- 51. Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B, et al. Associations between migraine and type 2 diabetes in women: findings from the E3N cohort study. JAMA Neurol. 2019;76(3):257–63.

- Hou WH, Li CY, Chang HH, Sun Y, Tsai CC. A population-based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus. J Epidemiol. 2017;27(5):235–41.
- Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology. 2018;90(22):e1954–63.
- Mokry LE, Ross S, Timpson NJ, Sawcer S, Davey Smith G, Richards JB. Obesity and multiple sclerosis: a Mendelian randomization study. PLoS Med. 2016;13(6):e1002053.
- Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409–20.
- Antonazzo IC, Riise T, Cortese M, Berge LI, Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: a nationwide cohort study. Cephalalgia. 2018;38(11):1759–64.
- Raevuori A, Suokas J, Haukka J, Gissler M, Linna M, Grainger M, et al. Highly increased risk of type 2 diabetes in patients with binge eating disorder and bulimia nervosa. Int J Eat Disord. 2015;48(6):555–62.
- Lydecker JA, Grilo CM. Comparing men and women with binge-eating disorder and co-morbid obesity. Int J Eat Disord. 2018;51(5):411–7.
- Nissen J, Powell S, Koch SV, Crowley JJ, Matthiesen M, Grice DE, et al. Diagnostic validity of early-onset obsessive-compulsive disorder in the Danish psychiatric central register: findings from a cohort sample. BMJ Open. 2017;7(9):e017172.
- Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, et al. Incidence rates and cumulative incidences of the full Spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry. 2020;77(2):155–64.
- Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014;71(5):573–81.
- 62. Porta M, Curletto G, Cipullo D, Rigault de la Longrais R, Trento M, Passera P, et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care. 2014;37(6):1668–74.
- Thomsen PH. The prognosis in early adulthood of child psychiatric patients: a case register study in Denmark. Acta Psychiatr Scand. 1990;81(1):89–93.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

